Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.

S A MacDiarmid1, R T Emery, S F Ferguson

  • 1Department of Urology, University of Arkansas College of Medicine and John L. McClellan Memorial Veteran's Administration Hospital, Little Rock, USA.

The Journal of Urology
|October 19, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The health of children adopted from Romania.

JAMA·1992
Same author

Workers' comp: more confusion over dispute resolution.

Texas medicine·1992
Same author

Epididymo-orchitis developing as a late manifestation of intravesical bacillus Calmette-Guerin therapy and masquerading as a primary testicular malignancy: a report of 2 cases.

The Journal of urology·1992
Same author

Maintenance energy requirement of llamas.

American journal of veterinary research·1992
Same author

Histopathologic and angiographic analysis of coronary artery morphology six months after triple artery angioplasty.

The American journal of cardiology·1992
Same author

Iron deficiency of liver, heart, and brain in newborn infants of diabetic mothers.

The Journal of pediatrics·1992

The 8 mg. dose of doxazosin showed greater efficacy than the 4 mg. dose for treating benign prostatic hyperplasia (BPH). Increasing the doxazosin dosage to 8 mg. is recommended for patients not adequately responding to 4 mg.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • Doxazosin is an alpha-1 blocker used to treat BPH symptoms.

Purpose of the Study:

  • To compare the efficacy of 4 mg versus 8 mg of doxazosin in patients with BPH.
  • To evaluate the impact of different doxazosin dosages on symptom scores and urinary flow rates.

Main Methods:

  • A double-blind study randomized 82 BPH patients already on 4 mg doxazosin to either 4 mg or 8 mg.
  • Patients were assessed using the American Urological Association (AUA) symptom score, Boyarsky score, uroflowmetry, and side effect profiles at baseline, 1 month, and 3 months.

Main Results:

  • The 8 mg group showed statistically significant improvements in Boyarsky scores (p <0.05) and AUA symptom scores (p <0.05) compared to the 4 mg group at 3 months.

Related Experiment Videos

  • No significant differences were observed in maximum urinary flow rate changes between the two groups (p >0.05).
  • Dropout rates and reported side effects were similar between the 4 mg and 8 mg doxazosin groups.

    • Conclusions:

    • An 8 mg dose of doxazosin is more efficacious than 4 mg for BPH treatment.
    • The 8 mg dose should be considered for patients not achieving adequate response or clinical improvement with 4 mg doxazosin, provided they tolerate the medication.